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Abstract 33 
Demographic factors potentially influencing the presentation and severity of IIH in US vs UK 34 
populations include obesity and ethnicity.  We aimed to compare the presenting features of IIH 35 
between populations in UK and US tertiary referral centres, to assess what population differences 36 
exist and whether these cause different presentations and impact on visual function. 37 
Methods 38 
Clinical data were collected on 243 consecutive UK IIH patients and 469 consecutive US IIH patients 39 
seen after 2012 in two tertiary centers. Visual function was defined as severe visual loss when HVF-40 
MD was <-15dB, GVF showed constriction or visual acuity was less than 20/200.   41 
Results 42 
US patients were more commonly of self-reported black race (58.9%vs7.1%) than UK patients, but 43 
had a similar mean BMI (38.3±0.63 kg/m2 UK vs 37.7±0.42 kg/m2 US; p=0.626).  The UK cohort had 44 
lower presenting Frisén grade (median 1 vs 2; p<0.001) and severe visual loss less frequently 45 
(15.4%vs5%; p=0.014) but there was no difference in mean CSF-OP (35.8±0.88 cmH2O UK vs 46 
36.3±0.52 cmH2O US; p=0.582).  African-Americans had poorer visual outcomes compared with US-47 
whites (19.4% vs 10% severe visual loss; p=0.011).  Visual function was weakly associated with CSF 48 
opening pressure (R2=0.059; p=0.001), which was similar between UK and US patients. 49 
Conclusions 50 
The UK and the US cohorts had a similar average presenting BMI.  However, the worse presenting 51 
visual function in the US IIH cohort was partially attributable to differences in the black populations 52 
in the two countries. 53 
 54 
  55 
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Introduction 56 
Idiopathic Intracranial Hypertension (IIH) is a rare disease, where there is international acceptance 57 
on diagnosis,1 but until recently less consensus on management.2, 3   Thus management may vary 58 
amongst treatment centres and, in addition, the presenting phenotype may be location-specific. 59 
Demographic factors that potentially influence the phenotype between IIH populations are body 60 
mass index (BMI) and ethnicity.  IIH is known to have a marked association with those who are 61 
obese. In particular truncal fat mass and higher BMI has been associated with more severe visual 62 
loss.4, 5  Obesity affects 30.4% of British women and 38.2% of American women6 (Table 1).   Previous 63 
work has identified that those of African-American descent with IIH are more likely than white US IIH 64 
patients to have severe visual loss,7 and 2.81% of the British population identified as black on the 65 
latest census data, compared with 13.4% in the US.8, 9     66 
IIH incidence is rising in England and worldwide 10 11, presumed to be related to the increasing global 67 
prevalence of obesity (Table 1).11, 12 The rise in CSF shunting procedures in the US between 1998 and 68 
2002, paralleled the rise in obesity rates over that same period.13  The international prevalence of IIH 69 
associates with the prevalence of obesity.11, 14  However, the proportion of obesity in IIH cohorts 70 
may vary independently of the overall population prevalence of obesity (Table 1).  Given the 71 
differences between the UK and US populations, we aimed to compare two large neuro-72 
ophthalmology IIH clinic cohorts from prospectively held databases in the two countries to assess for 73 
differences in the presenting phenotype. 74 
 75 
Methods 76 
The study was approved by the University Institutional Review Board at Emory and the local NHS 77 
National Research Ethics Committee (14/LO/1208) and conformed to the tenets of the Declaration 78 
of Helsinki.   79 
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We included consecutive patients over the age of 16 with a diagnosis of IIH, seen in one US and one 80 
UK tertiary referral centres.  Only patients with a diagnosis of IIH according to the modified Dandy 81 
criteria were included 1: specifically papilledema, normal neurologic examination except cranial 82 
nerve palsies, normal neuroimaging, normal CSF constituents and elevated lumbar puncture opening 83 
pressure (>25cm CSF).  The US cohort was a retrospectively collected cohort of consecutive patients 84 
evaluated in a standardised fashion by VB, NN and BB.  The UHB cohort was prospectively collected 85 
in consecutive patients with a diagnosis of IIH who consented to recruitment in the IIH: Life 86 
database. 87 
All patients were evaluated in a standardised manner by experienced neuro-ophthalmologists 88 
including complete neuro-ophthalmic history and examination with formal visual fields, fundus 89 
photography, neuro-imaging, height and weight.  UK data were collected and entered prospectively 90 
into the IIH:life database.  US data was entered retrospectively from the electronic patient record 91 
and written notes.   92 
Data collected included age, race, gender, BMI, recent weight gain, presenting symptoms (headache, 93 
tinnitus, diplopia, transient visual obscurations), visual acuity (VA), visual fields (VF), and CSF-94 
opening pressure (CSF-OP).  95 
US patients’ fundus images taken at or close to the time of initial presentation were Frisén-graded 96 
by 3 different neuro-ophthalmologists, all masked to clinical details.  For the UK dataset, 2 different 97 
neuro-ophthalmologists performed Frisén-grading on slit lamp examination at presentation 28.  98 
Disagreements were settled by referral to two additional observers.  UK patients’ disc appearance 99 
was graded in clinic at the time of recruitment by two experienced neuro-ophthalmologists.  Visual 100 
fields were graded as severe visual loss when the Humphrey Visual Field Mean Deviation was <-15 101 
dB or when Goldmann visual fields showed severe constriction.   102 
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Patients who reported use of medications that have been associated with intracranial hypertension 103 
were excluded (fluoroquinolone and tetracycline antibiotics, cyclosporin, vitamin A preparations, 104 
recent steroid discontinuation).  Alternative causes for intracranial hypertension were excluded at 105 
the time of diagnosis by full blood count checking for anaemia and review of imaging, including 106 
venography. 107 
Statistical analysis was performed in SPSS 21 (IBM Corp., Armonk, NY) and used t-test for continuous 108 
numeric data and Chi-squared for categorical data except for visual fields and visual acuity data.  109 
Because visual fields (MD) and visual acuity had two measurements per patient, they were analysed 110 
using generalised estimating equations.  To allow model fit, groups with few patients (e.g. 111 
transgender, South Asian race) were collapsed and combined.  In particular missing race data were 112 
combined with white race, because most patients with missing race data were from the UK cohort.  113 
To assess systemically the effect of these missing data, the data were also replaced with multiple 114 
imputation and pooled analyses are reported.  To minimise the risk of type 1 error, we analysed 115 
Frisén grading and severe visual field loss analysis, which are non-numeric data, for the worse eye 116 
only using Chi-squared tests.  Means are reported as mean ± standard error of the mean unless 117 
otherwise specified. 118 
Results 119 
Presenting Demographics 120 
Consecutive cohorts of 243 UK patients and 469 US patients presenting for evaluation of IIH after 121 
2012 in two tertiary centers were included.  One patient in the UK cohort was not included because 122 
she did not consent to inclusion in IIH: Life.  123 
US patients were more commonly of self-reported black race (58.9%vs7.1%; Table 2) and UK 124 
patients were more commonly of South Asian descent (8.8%vs1.0%), reflecting the ethnicity of the 125 
local populations surrounding the treatment centres.   126 
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There was no evidence that the UK and US patients differed in BMI (38.3±0.63 kg/m2 UK vs 127 
37.7±0.42 kg/m2 US; p=0.626; 95% CI for the difference -0.8 to 2.1) or in the proportion of obese 128 
patients (84.4% UK vs 79.7% US; p=0.147).   129 
The gender proportions were similar between UK and US patients (6% males US vs 4.1% UK; 130 
p=0.284).   131 
Visual Function 132 
Compared with US patients (Table 2), the UK cohort had better presenting VA (logMAR 0.09±0.02 vs 133 
0.15±0.02; p<0.001) and mean deviation (-4.74±0.40 vs -6.52±0.35 dB; p<0.001).  Frisén grade was 134 
also lower in UK patients (median 1 vs 2; p<0.001).  Because of the potential for systematic 135 
differences in how visual acuity and visual fields are assessed, we also looked at the proportion with 136 
severe visual loss, defined as diffusely constricted Goldmann visual fields or a MD<-15dB, as 137 
previously described. 16  The US patients were more likely to have severe VF loss at presentation 138 
(15.4%vs5%; p=0.014).   139 
There was no evidence of a difference in mean CSF-OP between UK and US patients (35.8±0.73 140 
cmH2O UK vs 36.3±0.46 cmH2O US; p=0.582).   141 
History 142 
Among symptomatic US patients, the mean reported duration of symptoms was 10.0±0.64 weeks; 143 
equivalent data on symptom duration were not available in the UK cohort.  The prevalence of 144 
headache as a presenting symptom was higher in UK than US patients (Table 3; 85vs65%; p<0.001). 145 
Incidental finding of papilledema on routine examination was also more common in UK than US 146 
patients (Table 3; 48%vs30%; p<0.001).  About half of the patients reported recent weight gain (54% 147 
UK vs 46% US; p=0.236). 148 
Variation in visual function at presentation 149 
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When the US and UK datasets were analysed together, Frisén grade and CSF opening pressure were 150 
weakly associated (R2=0.109, p<0.001).  CSF opening pressure was available on 539/712 patients 151 
(76%) and initial Frisén grade on 288/712 patients (40%).  When Frisén grade, CSF opening pressure, 152 
race, country, BMI and duration of symptoms were analysed together, CSF opening pressure and the 153 
interaction between race and country were independently associated with visual function at 154 
presentation (Table 4), assessed as mean deviation (R2=0.042, p<0.001).  155 
  156 
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The binary measure of visual function “severe visual loss in either eye” associated with race (p=0.02) 157 
and CSF opening pressure (p<0.001), but a model could not be fitted for the interaction term.  158 
(p<0.001; GEE binomial logit). 159 
To assess the effect of missing data, multiple imputation of the missing values with pooled analysis 160 
of the 10 imputed datasets yielded results consistent with the primary analysis: every 1cmH2O 161 
increase in CSF opening pressure was associated with a 0.168dB reduction in MD (p<0.001) and 162 
visual function was worse in African-American than white US patients by an average of 1.60dB 163 
(p=0.018), whereas UK African Caribbean visual function was, on average, 3.15dB better than in US 164 
white patients (p=0.039).   165 
Race 166 
Within the US cohort, African-American patients had a higher proportion of severe visual loss at 167 
presentation (19.4% vs 10%; p=0.011) and a worse mean deviation on visual field testing (-7.38±0.52 168 
vs -5.58±0.49 dB; p=0.003).  There was weak evidence of a difference in CSF opening pressure, which 169 
was higher in African-American patients (37.69±0.720 cmH2O vs 34.95±0.794 cmH2O; p=0.055), 170 
though minimal evidence of a difference in Frisén grade (median 3 African American vs 2 white; 171 
p=0.205).  There was no difference in presenting visual acuity (logMAR 0.14±0.03 white vs logMAR 172 
0.17±0.03 African American; p=0.857).  On average white patients had a longer duration of 173 
symptoms before presentation (11.5±1.13 weeks vs 9.02±0.75 weeks; p=0.042), but no difference in 174 
the proportion of patients with incidentally discovered papilloedema (24.1% African American vs 175 
26.3% white; p=0.624).   176 
There were 8 African Caribbean patients in the UK dataset, who had lower CSF opening pressures 177 
(33.4±1.81 vs 39.6±2.11 cmH2O; p=0.037) and better mean deviations on Humphrey visual field 178 
testing (-2.02 dB±0.63 vs -6.02 dB±0.85; p=0.001). 179 
Discussion 180 
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This collaborative study compared two large neuro-ophthalmology IIH clinic cohorts from 181 
prospectively held databases in the UK and the US and assessed for differences in the presenting 182 
phenotype between the two centres. US patients with IIH presented with significantly worse visual 183 
function, being more likely to have severe visual loss at presentation.  African-American patients in 184 
the US cohort had worse visual function than white patients, who had similar baseline features in 185 
both the US and UK cohorts.   186 
The more severe disease in African-American patients has been previously reported,7 and does not 187 
seem to be explained by different access to care in our cohort, because duration of symptoms and 188 
incidentally discovered papilledema was not different between white and African-American 189 
ethnicities.  Although duration of symptoms was not available in the UK cohort, there was a higher 190 
rate of incidental papilledema compared with the US cohort.  The higher prevalence of incidental 191 
papilloedema in the UK cohort is in contrast to the higher reported rate of headache in the UK and 192 
could be explained by access to care, as greater access to eye examinations may be expected to 193 
associate with greater incidental detection of papilloedema. . 194 
Visual function was similar in white US and white UK patients (0.76dB worse in US, p=0.192), in 195 
contrast to a previous comparison between white US and white French patients with IIH, 16 which 196 
found that white US patients had a longer pre-diagnosis duration of symptoms and were more likely 197 
to have visual field constriction and poor visual acuity at presentation. 198 
Table 1 shows a weak relationship between population obesity in the general population and IIIH 199 
patients.  A recent English paper reports not only an increase in the incidence of IIH between 2002 200 
and 2016, but the association with obesity over this time.10  In Iowa in 1988, the mean weight in an 201 
IIH population was 38% above ideal weight for height (BMI 34.5) and 67% were obese.29  At that 202 
time, 17.5% of the US population was obese.  Comparison with the recent IIIH cohorts suggests that 203 
the average weight of IIH patients has increased over time in concert with the increased prevalence 204 
of obesity in the population.  In the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), the 205 
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mean initial BMI was much higher, at 39.9, and in this trial recruitment was restricted to mild visual 206 
field defects with mean deviations less than 7 dB, although the study did not report the 207 
characteristics of patients declining to participate or failing screening.30   208 
The US has higher prevalences of both overweight and obesity than the UK (UK 68.6% male and 209 
58.9% female overweight, 26.9% male and 28.6% female obese; US 72.7% male and 63.2% female 210 
overweight, 35.5% male and 37% female obese).  The similar weights and proportions of obesity 211 
between US and UK IIH patients probably reflects that fact that only obese patients suffer from IIH 212 
and we do not have data on the average BMI of obese patients in the UK and US.  The equivalent 213 
average BMI in our US and UK IIH cohorts excludes degree of obesity as an explanatory factor in the 214 
more severe presentation of US patients.   215 
Similar to previous studies, most IIH patients were female.18, 31  In contrast to weight and gender, the 216 
racial mix of patients reflects the population local to the treatment centres, suggesting that whilst 217 
being African American confers a worse prognosis, it does not affect the risk of disease. 218 
The relationship between Frisén grade and CSF-OP has been previously reported in the IIHTT,32 219 
although there was no relationship between CSF-OP and baseline visual function in the IIHTT, which 220 
may be related to the exclusion of patients with severe visual loss from that population.  The 221 
association between high CSF-OP and visual loss has not been previously reported except that cases 222 
series of patients with fulminant disease have reported high CSF-OP.33  CSF-OP may affect visual 223 
function secondary to the association between Frisén grade and visual function, but does not appear 224 
to explain the observed UK-US differences and, with R2 < 0.1, has a modest effect. 225 
Conclusions 226 
Visual loss at presentation was more severe in the US cohort, despite similar BMIs and similar LP 227 
pressures.  The population differences in presenting visual function may relate to the higher 228 
proportion of patients of black race in the US population. 229 
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 Country 
Mean 
population BMI 
(kg/m2) 
Year 
Prevalence of 
IIH 
Incidence of 
IIH 
Mean BMI 
(kg/m2) 
Australia15 27.4 ‘17 7.9/100,000  
 
France16 25.6 ‘88 
  
33 
India17 21.8 ‘07 
  
27.7 
Israel18, 19 27.4 ’01-‘16 
 
0.94 32.2 
Italy14 26.3 ‘04 
 
0.28  
Japan20 22.8 ‘00 1/1000,000 0.03 only 2 cases 
Libya14 27.9 ‘93 
 
2.2 
 
Portugal18 26.2 ‘16 
  
34.8 
Spain21 26.6 ‘15 1.2/100,000  73.77% obese 
Sweden22 26.4 ‘17 1/100,000 0.65 34.4 
Switzerland18 25.7 ‘16 
  
36.4 
Turkey18 27.9 ‘16 
  
31.2 
UK18, 23 27.5 ’91-‘11 10.9/100,000 0.51 - 1.57  39.7 
US14, 16, 24, 25, 26 29.1 ‘98-‘11 8.9/100,000  0.9  31.8-34 
Table 1. Population and IIH rates of obesity.  Population data from the World Health Organisation27. 
 
 Parameter UK US P value 
Black race 7.10% 58.90% n/a 
Proportion with severe visual loss 
(%) 
5 15.4 0.014 
HVF mean deviation (dB) -4.74±0.40 -6.52±0.35 <0.001 
CSF Opening pressure (cmH20) 35.8±0.73 36.3±0.46 0.582 
Visual acuity (logMAR) 0.085±0.02 0.152±0.01 <0.001 
BMI (kg/cm2) 38.3±0.59 37.7±0.41 0.626 
Proportion female (%) 95.9±1.8 94.0±1.27 0.284 
Frisen grade 1 (IQR 1-2) 2 (IQR 1-3) <0.001 
Age (years) 31.7±0.51 32.8±0.58 0.17 
Table 2. Summary of presenting features. 
 
 Symptoms UK proportion (%) US proportion (%) p value (Chi squared) 
Incidental papilledema 48.1 30.0 <0.001 
Headache 85.4 65.0 <0.001 
Diplopia 14.6 11.0 0.207 
Nausea or vomiting 17.3 7.90 <0.001 
Neck or back pain 4.86 2.86 0.208 
Pulsatile tinnitus 43.2 17.2 <0.001 
Transient visual obscurations 28.1 21.1 0.058 
Other visual symptoms 40.0 35.0 .236 
Table 3. Presenting symptoms in UK and US IIH patients. 
 
 Modelled 
Comparison 
Effect Effect size (95% 
CI) 
P 
value 
US white vs US 
black 
Worse visual function in African American than 
white US patients 
1.55 dB (0.27-
2.83) 
0.018 
US white vs UK 
white 
Non-significant difference with worse visual 
function in US white 
0.76 dB (-0.38-
1.89) 
0.192 
CSF opening 
pressure 
Higher CSF pressure associated with worse visual 
function 
0.123 dB/cmH20 
(0.05-0.20) 
0.001 
Race * Country 
Interaction 
UK African Caribbean visual function is better than 
US white 
3.05 dB (0.82-
5.29) 
0.007 
Table 4. Model output for the comparison of race, nationality and CSF opening pressure. 
 
